 AUSTIN, Texas, June 18, 2021 PRNewswire -- Natera,Inc. NASDAQ: NTRA, a pioneer and global leader in cell-free DNA testing, today announced that the Centers for Medicare Medicaid Services CMS has granted ADLT status for the Signatera molecular residual disease MRD test. Obtaining ADLT status confirms that Signatera meets the highly selective criteria established under the Protecting Access to Medicare Act of 2014 PAMA. 